S.O.L.V.E.-AMR – Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance
Lyon – Dijon – Paris, Tuesday October 10th, 2023] – BIOASTER, Cynbiose, ICTA, and PharmaLex announced today a strategic collaboration that aims to help combat antimicrobial resistance (AMR). As part of the initiative, the organizations will leverage their collective expertise and capabilities to offer innovative and integrated support from discovery, pre-clinical and clinical drug development processes up to registration and commercialization, helping to accelerate the development of antimicrobials.
AMR, which occurs when a microorganism (bacteria, viruses, fungi, parasites) develops the ability to resist the effects of a drug, is a significant global public health threat. The World Health Organization (WHO), U.S. Government and European Commission each have initiated action plans against AMR. Boosting research, development and innovation—including developing new therapeutics and alternatives—is a key objective of the EU’s One Health Action Plan against AMR.